Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Share News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks start second half in green amid PMIs

Mon, 03rd Jul 2023 09:07

(Alliance News) - European markets rose at Monday's open, kicking off the start of the second half on a positive note, boosted by strong trading in Asia and New York,

The FTSE 100 index opened up 18.52 points, 0.3%, at 7,550.05. The FTSE 250 was up 72.89 points, 0.4%, at 18,489.65, and the AIM All-Share was up 0.65 point, 0.1%, at 754.16.

The Cboe UK 100 was up 0.2% at 753.09, the Cboe UK 250 was up 0.3% at 16,141.46, and the Cboe Small Companies was up 0.1% at 13,727.97.

"The FTSE 100 opened marginally higher, helped by the tailwinds of a strong session in Asia and on Wall Street on Friday. But it's still struggling to find significant momentum, dragged down by concerns about growth in China and the wider global economy," commented Hargreaves Lansdown's Susannah Streeter.

In European equities, the CAC 40 in Paris was up 0.2%, while the DAX 40 in Frankfurt was up 0.3%.

Shares in Tesla were up 5.2% in Frankfurt after the US automaker said deliveries in the second quarter beat market estimates.

The electric car maker delivered 466,140 vehicles, an 83% increase year-on-year and above estimates of 450,000.

"The electric vehicle giant has benefitted from US federal credits which are designed to encourage consumers to shift away from diesel and petrol cars," interactive investor's Victoria Scholar said. "Its strategy to cut prices this year has also paid off amid the macroeconomic headwinds but could weigh on profit margins ahead."

Tesla's production is still a long way below that of major car makers such as Toyota, which produced nearly 950,000 vehicles in May alone this year.

In Asia on Monday, markets took their cue from the strong performance on Wall Street, despite some mixed economic data for the region.

The Nikkei 225 index in Tokyo closed up 1.7%, with Toyota up 0.7%.

In China, the Shanghai Composite closed up 1.3%, while the Hang Seng index in Hong Kong was up 2.3%. The S&P/ASX 200 in Sydney closed up 0.6%.

Early economic data pointed towards a slowdown in Asian manufacturing.

The Caixin purchasing managers' index for China's manufacturing indicated marginal growth in June, albeit at a slower pace than in May. Meanwhile, the au Jibun Bank PMI for Japan showed its manufacturing sector slipped back into a slight contraction. Respondents in Japan noted especially weak demand from mainland China, with exports orders continuing to fall.

In the US on Friday, Wall Street ended higher, with the Dow Jones Industrial Average up 0.8%, the S&P 500 up 1.2% and the Nasdaq Composite up 1.5%. Sentiment was lifted by a cooler-than-expected US inflation print, which boosted hopes that the Federal Reserve's rate-rising spree might be close to an end.

Still, the dollar was firm against other major currencies in early exchanges in Europe on Monday.

Sterling was quoted at USD1.2670, lower than USD1.2706 at the London equities close on Friday. The euro traded at USD1.0880, lower from USD1.0916. Against the yen, the dollar was quoted at JPY144.75, up versus JPY144.58.

In London, supermarket chain Tesco rose 0.9% as it named Gerry Murphy as its new chair from September 1.

Murphy is currently chair of luxury fashion firm Burberry and food supplier Tate & Lyle, and will step down from his role at the latter to "ensure he has sufficient capacity" for his new role at Tesco.

Murphy was also previously CEO at Kingfisher, and has held non-executive directorships at companies including British American Tobacco and Reckitt Benckiser.

Shares in Tate & Lyle fell 0.5%, while Buberry was trading flat.

Anglo American rose 2.3%, as it announced late on Friday that its diamond business, de Beers, reached an eleventh-hour deal with the Botswanan government. This followed months of tense negotiations that saw the continent's top producer threatening to cut ties with the storied diamond company.

The Botswana government and Anglo-American, have reached an "agreement in principle", the two sides said in a statement issued late Friday. The agreement provides for a new 10-year agreement to sell the rough diamonds produced by Debswana – a joint venture equally owned by the government and De Beers – and a 25-year extension of its mining licenses.

AstraZeneca fell 5.9% in early trade - the worst large-cap performer - as it announced high-level results from the Tropian-Lung01 phase III trial.

The trial looked at datopotamab deruxtecan, or Dato-DXd, in advanced non-small cell lung cancer. In patients will locally advanced or metastatic NSCLC treated with at last one prior therapy, the treatment showed a "statistically significant" improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy.

However, for the dual primary endpoint of overalll survival, the data "were not mature".

"An early trend was observed in favour of datopotamab deruxtecan versus docetaxel that did not meet the prespecified threshold for statistical significance at this interim analysis," AstraZeneca said.

The trial will continue as planned in order to assess OS with greater security.

On AIM, Yourgene Health more than doubled in value, with its shares reaching 0.47 pence from 0.20p on Friday.

The molecular diagnostic group has agreed a cash takeover offer with Novacyt UK, a wholly-owned subsidiary of fellow AIM listing Novacyt. The offer of 0.522p a share values the company at GBP16.7 million.

Novacyt is a biotechnology group focused on clinical diagnostics. Its shares were up 16%.

"The acquisition combines highly complementary technologies and services, with the enlarged group able to leverage mutual research and development capabilities for ongoing product development and portfolio enhancement to improve the customer offering," the companies said.

Gold was quoted at USD1,916.08 an ounce early Monday, higher than USD1,915.48 on Friday. Brent oil was trading at USD75.28 a barrel, little changed from USD75.58

There are more manufacturing PMI readings to come, including the UK at 0930 BST and the US at 1445 BST.

Financial markets in New York close at 1300 local time on Monday for Independence Day. They stay closed on Tuesday for the US public holiday.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
10 Mar 2020 15:31

Yourgene Health acquires its French distribution partner

(Sharecast News) - Molecular diagnostics company Yourgene Health announced the acquisition of AGX-DPNI on Tuesday, which it described as a newly-formed entity comprising the NIPT distribution business of AdGeniX - its current French distribution partner for the 'IONA' test.

Read more
17 Feb 2020 12:49

Yourgene Health Takes Another Step Towards IONA CE Marking Certificate

Yourgene Health Takes Another Step Towards IONA CE Marking Certificate

Read more
17 Feb 2020 08:45

Yourgene submits CE-mark file for 'IONA' test

(Sharecast News) - Molecular diagnostics company Yourgene Health has submitted its CE-marking technical file for the Illumina-based 'IONA' test to its EU notified body, BSI Netherlands, it announced on Monday.

Read more
14 Feb 2020 14:47

Yourgene's 'Elucigene DPYD' approved for sale in Australia

(Sharecast News) - Molecular diagnostics company Yourgene Health announced on Friday that its chemotoxicity diagnostics assay, 'Elucigene DPYD', which tests to identify cancer patients at risk of lethal side effects from chemotherapy, has been approved for sale in Australia by the country's Therapeutic Goods Administration (TGA), as an in vitro diagnostic (IVD).

Read more
14 Feb 2020 09:44

Yourgene Health Says Cancer Test Elucigene Approved In Australia

Yourgene Health Says Cancer Test Elucigene Approved In Australia

Read more
2 Dec 2019 11:55

Yourgene Health Reports "Strong Growth", Supported By New Acquisition

Yourgene Health Reports "Strong Growth", Supported By New Acquisition

Read more
25 Nov 2019 15:57

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
14 Nov 2019 15:05

Concepta Hires BBI Healthcare Director As New Chief Executive Officer

Concepta Hires BBI Healthcare Director As New Chief Executive Officer

Read more
14 Oct 2019 09:08

Yourgene Health Revenue Doubles In First Half On International Growth

Yourgene Health Revenue Doubles In First Half On International Growth

Read more
14 Oct 2019 08:50

Yourgene Health revenues almost double during H1

(Sharecast News) - Molecular diagnostics company Yourgene Health saw top-line growth over the six months ended 30 September as international revenues continued to show "very strong momentum".

Read more
26 Sep 2019 13:24

Yourgene Health Transfers To Netherlands Notified Body Ahead Of Brexit

Yourgene Health Transfers To Netherlands Notified Body Ahead Of Brexit

Read more
17 Sep 2019 13:04

Yourgene Health On Schedule For New Prenatal And Oncology Tests

(Alliance News) - Yourgene Health PLC on Tuesday said it is on track to launch its new non-invasive prenatal test on the Illumina platform in early 2020.YourGene and Illumina agreed to a in

Read more
17 Sep 2019 10:05

Yourgene Health builds 'strong foundation' following 'transformational' period

(Sharecast News) - Molecular diagnostics group Yourgene Health told investors at its annual general meeting on Tuesday that it had built a "strong foundation" following a period of "transformational change".

Read more
16 Aug 2019 12:52

Yourgene Health Appoints Former Roche Diagnostics Director As Non-Exec

(Alliance News) - Yourgene Health PLC on Friday said it appointed Jonathan Seaton as a non-executive director, with immediate effect.The molecular diagnostics company said Seaton has for at

Read more
29 Jul 2019 11:50

Yourgene Health Appoints John Brown As Non-Executive Director

LONDON (Alliance News) - Yourgene Health PLC, which develops treatment for Down's syndrome and other genetic disorders, said Monday that it has appointed John Brown as non-executive director -

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.